A case report of long term bevacizumab treatment in multiresistant ovarian cancer

Anette Stolberg Kargo, Parvin Adimi, Karina Dahl-Steffensen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

307 Downloads (Pure)

Abstrakt

Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic treatment. Anti-angiogenic treatments have a less toxic profile, and bevacizumab has shown improvement of progression free survival (PFS) in front-line trials. Bevacizumab is generally introduced in combination with chemotherapy; however this case report will describe the use of single-agent bevacizumab for more than five years (102 cycles) in a patient with relapse of advanced ovarian cancer
OriginalsprogEngelsk
Artikelnummer4214
TidsskriftInternational Journal of Cancer Therapy and Oncology
Vol/bind4
Udgave nummer2
Antal sider4
ISSN2330-4049
DOI
StatusUdgivet - 19. jun. 2016

Citationsformater